Global Lichen Nitidus Treatment Market Size, Share, Forecast Report, 2020-2027

Lichen nitidus is a rare, chronic skin disease characterized by flat-topped, and skin-colored micropapules. Characteristics of these micropapules are the size, shape (pin point), color, location and itching. It mostly affects geriatric and pediatric population. They commonly occur on the chest, abdomen, arms and genital areas, including the penis. In this disease, T lymphocytes get activated resulting in the formation of these micropapules. In lichen nitidus, linear arrangement of micropapules can be seen on the fore arm or affected area.

Increasing prevalence of skin diseases across the globe is the major factor contributing the growth of the market. Unawareness about rare skin diseases among people may act as a restrain for the market growth.

The global lichen nitidus treatment market is expected to grow at a CAGR of 8.7% during the forecast period and is estimated to reach USD 170 million by 2023.

Segments
The global lichen nitidus treatment market is segmented on the basis of types, which includes oral and topical treatment. On the basis of treatment, the market is segmented into corticosteroids, retinoid, antihistamines, phototherapy and other treatment. On the basis of end user, the market is segmented into hospitals, dermatology clinics, and other
Key Players in the Global Lichen nitidus treatment Market
Some of the key players in this market are Pfizer Inc. (U.S), Novartis AG (Switzerland), Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. (U.S), Sanofi (France), GlaxoSmithKline plc. (U.K), AstraZeneca (U.K), Hubei Gedian Humanwell Pharmaceutical Co.,Ltd (China), Farmabios SPA (Italy), Horizon Pharma plc. (Ireland).